Insulin resistance, polycystic ovary syndrome and metf ormin

Drugs

Volumn 58, Issue SUPPL. 1, 1999, Pages 41-46

  Ptigeat, Michel ^a   Ditclnzean, Pierre Henri ^a  

^a Hopital de l'Antiquaille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; HYDROXYPROGESTERONE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT;

ANDROGEN SYNTHESIS; CONFERENCE PAPER; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME;

EID: 0032699818     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Franks S. Polycystic ovary syndrome. N Encl J Med 1995; 333: 853-61
2. Poison DW, Wadsworth J, Adams J, et ai. Polycystic ovaries a common finding in normal women. Lancet 1988; 1: 870-2
3. Dahlgren E, Johansson S, Lindstedt G, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992; 57: 505-13
4. Dahlgren E, Janson PO, Johansson S, et al. Polycystic ovary syndrome and risk for myocardial infarction - evaluated from a risk factor model based on a prospective study of women. Acta Obstet Gynecol Scand 1992; 71: 599-604
5. Conway GS, Agrawal R, Betteridge DJ, et al. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol 1992; 37: 119-25
6. Robinson S, Henderson AD, Gelding SV, et al. Dyslipidemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol 1996; 44: 277-84
7. Franks S. Polycystic ovary syndrome: approaching the millennium. Hum Reprod 1997; 12 Natl. Suppl.: 43-5
8. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Rev 1997; 6: 774-800
9. Dunaif A, Xia J, Book C, et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96: 801-10
10. Lcgro RS. The genetics of polycystic ovary syndrome. Am J Med 1995;98:9S-16S
11. Carey AH, Chan KL, Short F, et al. Evidence for a single gène effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol 1993; 38 (6): 653-8
12. Bates G, Whitworth MS. Effect of body weight reduction on plasma androgens in obese, infertile women. Fertil Steril 1982; 38: 409
13. Pasquali R, Antenucci D, Casimiiri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68: 173-9
14. Kiddy DS, Hamilton-Fairley D, Seppälä M, et al. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries; correlation with insulin and insulin-like growth factor-I. Clin Endocrinol 1989; 31:757-63
15. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992;36: 105-11
16. Nicolas MH, Crave JC, Fimbel S, et al. Hyperandrogénie de la femme hirsute et obèse, effets d'un régime hypocalorique. Presse Méd 1993; 22: 19-22
17. Guzick DS, Wing R, Smith D, et al. Endocrine conséquences of weisht loss in obese, hyperandrogenic, anovulatory womenrFertil Steril 1994; 61: 598-604
18. Clark AM, Ledger W, Gallety C, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995; 10: 2705-12
19. Hollman M, Runnebaum B, Gerhard I. Effects of weight loss on the hormonal profile in obese, infertile women. Hum Reprod 1996; 11: 1884-91
20. Jakubowicz DJ, Nestler JE. 17a-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab 1997; 82: 556-60
21. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocrine Rev 1995; 13:322-53
22. Hopkinson ZEC, Sattar N, Fleming R, et al. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. BMJ 1998; 317: 329-32
23. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-9
24. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. The Multicenter Metformin Study group. J Clin Endocrinol Metab 1991; 73: 1294-1301
25. Sattar N, Hopkinson ZEC, Gréer IA. Insulin-sensitising agents in polycystic ovary syndrome. Lancet 1998; 351: 305-6
26. Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647-54
27. Velazquez EM, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90: 392-5
28. Velazquez EM, Mendoza SG, Wang P, et al. Metformin therapy is associated with decreased plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with polycystic ovary syndrome. Metabolism 1997; 46: 454-7
29. Acbay O, Gündogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 1996; 65: 946-9
30. Ehrmann DA, Cavaghan MK, Imperial J, et al. Effect of metformin on insulin secretion, insulin action, and ovarian steroidoeenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 524-30
31. Nestler JE, Jakubowicz D. Decrease in ovarian cytochrome P450c 17a activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N EncI J Med 1996; 335: 617-23
32. Nestler JE, Jakubowicz D. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovar-ian P450cl7α activity and serum androgens. J Clin Endocrinol Metab 1997; 82: 4075-9
33. Diamantis-Kandarakis E, Kouli C.Tsianatelli T, et al.Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 199sfl3S: 269-74
34. Morin-Papunen LC, Koivunen RM, Ruokoncn A, et al. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998; 69: 691-6
35. Morin-Papunen LC, Koivunen RM, Tomas C, et al. Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 2566-8
36. Nestler JE, Jakubowicz DJ, Evans WS, et al. Effects of metformin on spontaneous and clomiphene-induced ovula-tion in the polycystic ovary syndrome. N Engl J Med 1998; 338: 1876-80
37. Crave J, Fimbel S, Lejeune H, et al. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995; 80: 2057-62
38. Coetzee EJ, Jackson WPU. Metformin in the management of pregnant insulin-dependent diabetics. Diabetologia 1979; 16: 241-5